900 related articles for article (PubMed ID: 17909059)
1. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
2. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
3. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
Meng XW; Lee SH; Dai H; Loegering D; Yu C; Flatten K; Schneider P; Dai NT; Kumar SK; Smith BD; Karp JE; Adjei AA; Kaufmann SH
J Biol Chem; 2007 Oct; 282(41):29831-46. PubMed ID: 17698840
[TBL] [Abstract][Full Text] [Related]
4. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
Rahmani M; Davis EM; Bauer C; Dent P; Grant S
J Biol Chem; 2005 Oct; 280(42):35217-27. PubMed ID: 16109713
[TBL] [Abstract][Full Text] [Related]
6. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Guo F; Sigua C; Tao J; Bali P; George P; Li Y; Wittmann S; Moscinski L; Atadja P; Bhalla K
Cancer Res; 2004 Apr; 64(7):2580-9. PubMed ID: 15059915
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Sinicrope FA
Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Dasmahapatra G; Yerram N; Dai Y; Dent P; Grant S
Clin Cancer Res; 2007 Jul; 13(14):4280-90. PubMed ID: 17634558
[TBL] [Abstract][Full Text] [Related]
9. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
10. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
11. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
Llobet D; Eritja N; Yeramian A; Pallares J; Sorolla A; Domingo M; Santacana M; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
Eur J Cancer; 2010 Mar; 46(4):836-50. PubMed ID: 20071162
[TBL] [Abstract][Full Text] [Related]
12. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
Gillespie S; Borrow J; Zhang XD; Hersey P
Apoptosis; 2006 Dec; 11(12):2251-65. PubMed ID: 17051334
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
[TBL] [Abstract][Full Text] [Related]
16. Mcl-1: a gateway to TRAIL sensitization.
Kim SH; Ricci MS; El-Deiry WS
Cancer Res; 2008 Apr; 68(7):2062-4. PubMed ID: 18381408
[TBL] [Abstract][Full Text] [Related]
17. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5.
Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ
Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496
[TBL] [Abstract][Full Text] [Related]
18. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
19. Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.
Gillissen B; Richter A; Richter A; Preissner R; Schulze-Osthoff K; Essmann F; Daniel PT
J Biol Chem; 2017 Apr; 292(16):6478-6492. PubMed ID: 28154184
[TBL] [Abstract][Full Text] [Related]
20. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
